Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma (METT)

Yong-Kil Hong

Status and phase: Completed; Phase 2

Conditions: Glioblastoma

Treatments: Drug: Temozolomide+Metformin; Drug: Temozolomide+Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT03243851

KNOG-1501

Details and patient eligibility

About

A phase 2 clinical trial for the efficacy and safety of low dose Temozolomide plus metformin as combination chemotherapy compared with low dose Temozolomide plus placebo in patient with recurrent or refractory Glioblastoma

Full description

Studies will investigate the efficacy and safety of low dose Temozolomide with Metformin or placebo for the patients with recurrent or refractory Glioblastoma.

The dosage of the Metformin will follow the domestically permitted dose to minimize side effects.

The patients will be allocated randomly to arm 1(experimental) and arm 2(placebo controlled) and administered the investigational products for up to 6 cycle. Each cycle consists of 4 weeks.

After 6 cycle(24 weeks), the patients will be checked progression and survival every 24 weeks up to 96 weeks.

Enrollment: 81 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Progressive or recurrent Glioblastoma conformed by histopathological or radiological diagnosis. Progressive or recurrent Glioblastoma during or after standard therapy (Temozolomide after Temozolomide and radiation therapy; Stupp regimen) after histopathological diagnosis of Glioblastoma Recurrence or progression is diagnosed according to histopathological diagnosis or revised RANO(Response Assessment in Neuro-Oncology) criteria c

2. Karnofsky performance status(KPS) ≥ 60%

3. Age ≥ 19 years old

4. At least 4 weeks after operation or chemotherapy

5. Normal in hematological finding, liver and kidney function

   • Hematology ANC > 1.500/mm³, Platelet > 100,000/mm³, WBC > 3×10^9/L, Hemoglobin > 9g/dL
   • Liver function Total Bilirubin level ≤ 1.5×ULN(in case of isolated hyperbilirubinemia ≤2.5 x ULN) AST / ALT < 2.5×ULN
   • Renal function Serum creatinine ≤ 1.5mg/dL

6. Be informed of the nature of the study and obtained a written informed consent

7. A legal representative agrees to the trial when a subject is unable to communicate smoothly due to neurologic defect

8. If a fertile woman who has been confirmed negative to a urine or blood pregnancy test within 28 days prior to the trial

Exclusion criteria

1. Pregnant or breast feeding

2. Cancer history within 5 years excluding cancer in the skin cells and cervix

3. Active infections within two weeks

4. Leptomeningeal metastasis

5. Patients diagnosed with diabetes

6. Hypersensitive or intolerance to Metformin

7. Patients who are currently taking Metformin, sulfonylureas, thiazolidinediones, and insulin, regardless of reason

8. Other serious diseases or medical conditions that include :

   • Patients who suffer from unstable heart disease despite treatment.
   • Patients having a heart attack within 6 months prior to the start of trial
   • Patients who suffer from severe nerve or psychosis that includes dementia or strokes.
   • Patients with an uncontrolled infection
   • Patient with uncontrolled hypertension, congestive heart failure, unstable angina, or incomplete arrhythmia

9. Those who have participated in other clinical trials may not recover from the toxicity of the treatment.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

81 participants in 2 patient groups, including a placebo group

Temozolomide+metformin

Experimental group

Description:

Temozolomide : 1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks Metformin : 1. 1st cycle (4 weeks) * 1 week(1st\~7th day) = 1,000mg/day * 1 week(8th\~14th day) = 1,500mg/day * 2 weeks(15th \~28th day) = 2,000mg/day 2. 2nd to 6th cycle (20 weeks) = 2,000mg/day

Treatment:

Drug: Temozolomide+Metformin

Temozolomide+placebo

Placebo Comparator group

Description:

Temozolomide : 1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks Placebo: 1. 1st cycle (4 weeks) * 1 week(1st\~7th day) = 1,000mg/day * 1 week(8th\~14th day) = 1,500mg/day * 2 weeks(15th\~28th day) = 2,000mg/day 2. 2nd to 6th cycle (20 weeks) = 2,000mg/day

Treatment:

Drug: Temozolomide+Placebo